AstraZeneca (GB:AZN) has released an update.
AstraZeneca’s drugs Imfinzi and Lynparza have been recommended by the European Medicines Agency’s CHMP for approval as treatments for certain advanced or recurrent endometrial cancers. This recommendation is based on the DUO-E Phase III trial results, which demonstrated significant improvements in progression-free survival compared to chemotherapy alone. If approved, this will offer new treatment options for patients in Europe, addressing a substantial unmet need, particularly for the majority with mismatch repair proficient disease.
For further insights into GB:AZN stock, check out TipRanks’ Stock Analysis page.
